Italy's National Agency for Regional Health Services (Agenas) Names Zimmer(R) NexGen(R) LPS Knee the Most Cost-Effective Total Knee Replacement Implant

WINTERTHUR, Switzerland, December 14, 2010 - Zimmer Holdings, Inc. (NYSE: ZMH; SIX: ZMH), a leader in musculoskeletal
care, today announced that the Zimmer NexGen LPS knee was ranked the most
cost-effective multiradius design total knee replacement implant in Italy in
a recent health technology assessment by Italy's National Agency for Regional
Health Services.(1)

The assessment identified the prostheses used in Italy for total knee
replacements, examined their performance based on clinical studies and
arthroplasty registers and constructed a cost-effectiveness model to support
buying decisions. The study collected data from 172 public hospitals and
private accredited providers of the Italian National Health Service.
Researchers focused on patients aged 50 and older who had received a primary
implant with a minimum follow-up period of five years.

"Knee replacement surgery is a highly effective treatment that restores
active lives to thousands of patients each year," said Oriol Lacorte, Vice
President Marketing EMEA. "As the world's leading provider of knee implant
technologies, we are proud to receive this recognition for our NexGen LPS
system which has a long history of cost-effective clinical success."

Since its introduction in 1996, Zimmer's NexGen LPS implant has
frequently been used for first-time knee replacement patients. It is a
posterior stabilized implant, intended for patients who have adequate bone
stock with ligaments that provide moderate joint stability or when the
posterior cruciate ligament (PCL) has been cut or removed. The NexGen LPS
system is part of Zimmer's NexGen family of products, one of Zimmer's
best-selling knee brands with over one million knees implanted worldwide
since its introduction. The NexGen knee system is a completely modular
system. Its success is built on multiple technologies such as Prolong(R)
Highly Crosslinked Polyethylene, Trabecular Metal(TM) technology, safe
high-flexion designs up to 155 degrees and anatomical fit for gender-specific
needs.

For more information about the NexGen family of products, please visit
www.zimmer.com.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs,
develops, manufactures and markets orthopaedic reconstructive, spinal and
trauma devices, dental implants, and related surgical products. Zimmer has
operations in more than 25 countries around the world and sells products in
more than 100 countries. Zimmer's 2009 sales were approximately $4.1 billion.
The Company is supported by the efforts of more than 8,000 employees
worldwide.

For more information about Zimmer, visit www.zimmer.com

(1) Cerbo M., Fella D, Jefferson T, Migliore A, Paone S, Perrini MR
Velardi L. Agenas HTA Report - Prostheses for primary total knee replacement
in Italy. Rome, July 2009.

Zimmer Safe Harbor Statement

This press release contains forward-looking statements within the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995
based on current expectations, estimates, forecasts and projections about the
orthopaedics industry, management's beliefs and assumptions made by
management. Forward-looking statements may be identified by the use of
forward-looking terms such as "may," "will," "expects," "believes,"
"anticipates," "plans," "estimates," "projects," "assumes," "guides,"
"targets," "forecasts," and "seeks" or the negative of such terms or other
variations on such terms or comparable terminology. These statements are not
guarantees of future performance and involve risks, uncertainties and
assumptions that could cause actual outcomes and results to differ
materially. For a list and description of such risks and uncertainties, see
our periodic reports filed with the U.S. Securities and Exchange Commission.
We disclaim any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise, except as may be set forth in our periodic reports.
Readers of this document are cautioned not to place undue reliance on these
forward-looking statements, since, while we believe the assumptions on which
the forward-looking statements are based are reasonable, there can be no
assurance that these forward-looking statements will prove to be accurate.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

Media: Sabine Ciccotosto, +41(0)52-262-72-41, sabine.ciccotosto at zimmer.com, Investors: Paul Blair, +1-574-371-8042, paul.blair at zimmer.com